BofA/Merrill Upgrade BioCryst to Buy from Underperform

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
10 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Feb 11, 2011

Shares of BioCryst (BCRX) are higher in morning trade as the company is reportedly upgraded to Buy from Underperform at BofA/Merrill.

The firm made the call citing the gout drug BCX4208 potential for the upgrade.

The firm has a $7 price target on company shares. That is up from $5.

Category:

News & Politics

Tags:

License:

Standard YouTube License

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more